IMV (TSE:IMV) Earns Buy Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of IMV (TSE:IMV) in a research report report published on Wednesday, PriceTargets.com reports. The firm issued a buy rating and a C$4.00 price objective on the stock. Cantor Fitzgerald also issued estimates for IMV’s FY2021 earnings at ($0.48) EPS and FY2022 earnings at ($0.44) EPS.

Other analysts have also recently issued research reports about the stock. Raymond James cut their price target on shares of IMV to C$2.50 and set a market perform rating for the company in a research note on Friday, July 16th. National Bank Financial reiterated a sector perform market weight rating on shares of IMV in a research note on Wednesday, August 11th. Three research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, IMV currently has a consensus rating of Hold and a consensus target price of C$3.75.

Shares of IMV opened at C$2.19 on Wednesday. IMV has a 12 month low of C$1.68 and a 12 month high of C$6.29. The firm has a fifty day simple moving average of C$2.12 and a 200 day simple moving average of C$2.84. The stock has a market capitalization of C$179.89 million and a price-to-earnings ratio of -3.95. The company has a current ratio of 5.11, a quick ratio of 4.25 and a debt-to-equity ratio of 39.14.

IMV (TSE:IMV) last announced its quarterly earnings results on Wednesday, August 11th. The company reported C($0.14) EPS for the quarter, meeting analysts’ consensus estimates of C($0.14). The firm had revenue of C$0.05 million during the quarter. As a group, research analysts predict that IMV will post -0.5 earnings per share for the current fiscal year.

IMV Company Profile

IMV Inc, a biopharmaceutical company, focuses on the development of cancer immunotherapies and vaccines against infectious diseases using its DPX delivery technology platform. The company's lead drug candidate includes maveropepimut-S (DPX-Survivac), a T cell therapy, which is in three Phase II clinical trials across 6 different cancer indications with and without Merck's Keytruda; and Phase II clinical trials for the treatment of ovarian cancer, and recurrent and refractory diffuse large B cell lymphoma.

Further Reading: Inflation

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.